Advertisement

Gene Delivery and Gene Therapy for Alzheimer’s Disease

  • Maya Woodbury
  • Tomomi Kiyota
  • Tsuneya IkezuEmail author
Protocol
Part of the Neuromethods book series (NM, volume 98)

Abstract

Adeno-associated virus (AAV) is the most widely used vector for gene therapy clinical trials focused on neurodegeneration. Not only can it safely and efficiently confer long-term expression in a variety of cell types, but innovations including hybrid serotypes, rationally designed capsids, split vectors, specific promoter/enhancer additions, and convection-enhanced delivery have greatly progressed the field of AAV research for neurodegenerative disease. Indeed, these developments, which enable increased specificity, efficiency, and spread of gene transfer as well as ease of administration to the CNS, have pushed AAV forward into clinical trials for Alzheimer’s disease. Preclinical testing of AAV gene transfer efficacy in animal models of disease has thus intensified. In this chapter, we provide detailed methods for construction of AAV expression vectors, their application in preclinical studies using established animal models of Alzheimer’s disease, and evaluation methods to assess Alzheimer’s disease-like behavior and brain pathology.

Key words

Adeno-associated virus Alzheimer’s disease Gene therapy 

References

  1. 1.
    Lim ST, Airavaara M, Harvey BK (2010) Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61:14–26PubMedCentralPubMedGoogle Scholar
  2. 2.
    Atchison RW, Casto BC, Hammon WM (1965) Adenovirus-associated defective virus particles. Science 149:754–756PubMedGoogle Scholar
  3. 3.
    Hoggan MD, Blacklow NR, Rowe WP (1966) Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc Natl Acad Sci U S A 55:1467–1474PubMedCentralPubMedGoogle Scholar
  4. 4.
    Casto BC, Atchison RW, Hammon WM (1967) Studies on the relationship between adeno-associated virus type I (AAV-1) and adenoviruses. I. Replication of AAV-1 in certain cell cultures and its effect on helper adenovirus. Virology 32:52–59PubMedGoogle Scholar
  5. 5.
    Berns KI, Kotin RM, Labow MA (1988) Regulation of adeno-associated virus DNA replication. Biochim Biophys Acta 951:425–429PubMedGoogle Scholar
  6. 6.
    Russell DW, Alexander IE, Miller AD (1995) DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A 92:5719–5723PubMedCentralPubMedGoogle Scholar
  7. 7.
    Yakobson B, Hrynko TA, Peak MJ et al (1989) Replication of adeno-associated virus in cells irradiated with UV light at 254 nm. J Virol 63:1023–1030PubMedCentralPubMedGoogle Scholar
  8. 8.
    King JA, Dubielzig R, Grimm D et al (2001) DNA helicase-mediated packaging of adeno-associated virus type 2 genomes into preformed capsids. EMBO J 20:3282–3291PubMedCentralPubMedGoogle Scholar
  9. 9.
    McLaughlin SK, Collis P, Hermonat PL et al (1988) Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol 62:1963–1973PubMedCentralPubMedGoogle Scholar
  10. 10.
    Samulski RJ, Chang LS, Shenk T (1989) Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 63:3822–3828PubMedCentralPubMedGoogle Scholar
  11. 11.
    Berns KI, Pinkerton TC, Thomas GF et al (1975) Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 68:556–560PubMedGoogle Scholar
  12. 12.
    Weinberg MS, Samulski RJ, McCown TJ (2012) Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology 69:82–88PubMedGoogle Scholar
  13. 13.
    Chirmule N, Propert K, Magosin S et al (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574–1583PubMedGoogle Scholar
  14. 14.
    Kotin RM, Siniscalco M, Samulski RJ et al (1990) Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A 87:2211–2215PubMedCentralPubMedGoogle Scholar
  15. 15.
    Samulski RJ, Zhu X, Xiao X et al (1991) Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10:3941–3950PubMedCentralPubMedGoogle Scholar
  16. 16.
    Weitzman MD, Kyostio SR, Kotin RM et al (1994) Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci U S A 91:5808–5812PubMedCentralPubMedGoogle Scholar
  17. 17.
    Balague C, Kalla M, Zhang WW (1997) Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 71:3299–3306PubMedCentralPubMedGoogle Scholar
  18. 18.
    Cheung AK, Hoggan MD, Hauswirth WW et al (1980) Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol 33:739–748PubMedCentralPubMedGoogle Scholar
  19. 19.
    Flannery JG, Zolotukhin S, Vaquero MI et al (1997) Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 94:6916–6921PubMedCentralPubMedGoogle Scholar
  20. 20.
    Xiao X, Li J, Samulski RJ (1996) Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70:8098–8108PubMedCentralPubMedGoogle Scholar
  21. 21.
    Fisher KJ, Jooss K, Alston J et al (1997) Recombinant adeno-associated virus for muscle directed gene therapy. Nat Med 3:306–312PubMedGoogle Scholar
  22. 22.
    Ponnazhagan S, Mukherjee P, Yoder MC et al (1997) Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. Gene 190:203–210PubMedGoogle Scholar
  23. 23.
    Kaplitt MG, Leone P, Samulski RJ et al (1994) Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8:148–154PubMedGoogle Scholar
  24. 24.
    McCown TJ, Xiao X, Li J et al (1996) Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res 713:99–107PubMedGoogle Scholar
  25. 25.
    Xiao X, Li J, McCown TJ et al (1997) Gene transfer by adeno-associated virus vectors into the central nervous system. Exp Neurol 144:113–124PubMedGoogle Scholar
  26. 26.
    Li J, Wang D, Qian S et al (2003) Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther 10:1807–1813PubMedGoogle Scholar
  27. 27.
    Monahan PE, Samulski RJ, Tazelaar J et al (1998) Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther 5:40–49PubMedGoogle Scholar
  28. 28.
    Grieger JC, Samulski RJ (2012) Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 507:229–254PubMedGoogle Scholar
  29. 29.
    Harris JA, Devidze N, Verret L et al (2010) Transsynaptic progression of amyloid-beta-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron 68:428–441PubMedCentralPubMedGoogle Scholar
  30. 30.
    Wu Z, Asokan A, Grieger JC et al (2006) Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J Virol 80:11393–11397PubMedCentralPubMedGoogle Scholar
  31. 31.
    Samulski RJ, Berns KI, Tan M et al (1982) Cloning of adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A 79:2077–2081PubMedCentralPubMedGoogle Scholar
  32. 32.
    Burger C, Gorbatyuk OS, Velardo MJ et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302–317PubMedGoogle Scholar
  33. 33.
    Cearley CN, Wolfe JH (2006) Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain. Mol Ther 13:528–537PubMedGoogle Scholar
  34. 34.
    Klein RL, Dayton RD, Tatom JB et al (2008) Tau expression levels from various adeno-associated virus vector serotypes produce graded neurodegenerative disease states. Eur J Neurosci 27:1615–1625PubMedCentralPubMedGoogle Scholar
  35. 35.
    Choi VW, McCarty DM, Samulski RJ (2005) AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther 5:299–310PubMedCentralPubMedGoogle Scholar
  36. 36.
    Parks WP, Boucher DW, Melnick JL et al (1970) Seroepidemiological and ecological studies of the adenovirus-associated satellite viruses. Infect Immun 2:716–722PubMedCentralPubMedGoogle Scholar
  37. 37.
    Xiao W, Chirmule N, Berta SC et al (1999) Gene therapy vectors based on adeno-associated virus type 1. J Virol 73:3994–4003PubMedCentralPubMedGoogle Scholar
  38. 38.
    Zincarelli C, Soltys S, Rengo G et al (2008) Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 16:1073–1080PubMedGoogle Scholar
  39. 39.
    Gao G, Vandenberghe LH, Alvira MR et al (2004) Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78:6381–6388PubMedCentralPubMedGoogle Scholar
  40. 40.
    Klein RL, Dayton RD, Leidenheimer NJ et al (2006) Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins. Mol Ther 13:517–527PubMedCentralPubMedGoogle Scholar
  41. 41.
    Gray SJ, Matagne V, Bachaboina L et al (2011) Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther 19:1058–1069PubMedCentralPubMedGoogle Scholar
  42. 42.
    Dodiya HB, Bjorklund T, Stansell J 3rd et al (2010) Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 18:579–587PubMedCentralPubMedGoogle Scholar
  43. 43.
    Foust KD, Nurre E, Montgomery CL et al (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59–65PubMedCentralPubMedGoogle Scholar
  44. 44.
    Bevan AK, Duque S, Foust KD et al (2011) Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 19:1971–1980PubMedCentralPubMedGoogle Scholar
  45. 45.
    Dayton RD, Wang DB, Klein RL (2012) The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther 12:757–766PubMedCentralPubMedGoogle Scholar
  46. 46.
    Allay JA, Sleep S, Long S et al (2011) Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther 22:595–604PubMedCentralPubMedGoogle Scholar
  47. 47.
    Masamizu Y, Okada T, Kawasaki K et al (2011) Local and retrograde gene transfer into primate neuronal pathways via adeno-associated virus serotype 8 and 9. Neuroscience 193:249–258PubMedGoogle Scholar
  48. 48.
    Gray SJ, Blake BL, Criswell HE et al (2010) Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther 18:570–578PubMedCentralPubMedGoogle Scholar
  49. 49.
    Bowles DE, McPhee SW, Li C et al (2012) Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther 20:443–455PubMedCentralPubMedGoogle Scholar
  50. 50.
    Peel AL, Klein RL (2000) Adeno-associated virus vectors: activity and applications in the CNS. J Neurosci Methods 98:95–104PubMedGoogle Scholar
  51. 51.
    Gray SJ, Foti SB, Schwartz JW et al (2011) Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther 22:1143–1153PubMedCentralPubMedGoogle Scholar
  52. 52.
    Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193–199PubMedGoogle Scholar
  53. 53.
    Klein RL, Hamby ME, Gong Y et al (2002) Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 176:66–74PubMedGoogle Scholar
  54. 54.
    Chen H, McCarty DM, Bruce AT et al (1999) Oligodendrocyte-specific gene expression in mouse brain: use of a myelin-forming cell type-specific promoter in an adeno-associated virus. J Neurosci Res 55:504–513PubMedGoogle Scholar
  55. 55.
    Feng X, Eide FF, Jiang H et al (2004) Adeno-associated viral vector-mediated ApoE expression in Alzheimer’s disease mice: low CNS immune response, long-term expression, and astrocyte specificity. Front Biosci 9:1540–1546PubMedGoogle Scholar
  56. 56.
    Lawlor PA, Bland RJ, Mouravlev A et al (2009) Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17:1692–1702PubMedCentralPubMedGoogle Scholar
  57. 57.
    Loeb JE, Cordier WS, Harris ME et al (1999) Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: implications for gene therapy. Hum Gene Ther 10:2295–2305PubMedGoogle Scholar
  58. 58.
    Yan Z, Zhang Y, Duan D et al (2000) Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci U S A 97:6716–6721PubMedCentralPubMedGoogle Scholar
  59. 59.
    Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21:583–593PubMedCentralPubMedGoogle Scholar
  60. 60.
    Xiao X, Li J, Samulski RJ (1998) Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 72:2224–2232PubMedCentralPubMedGoogle Scholar
  61. 61.
    Grimm D, Kern A, Rittner K et al (1998) Novel tools for production and purification of recombinant adeno-associated virus vectors. Hum Gene Ther 9:2745–2760PubMedGoogle Scholar
  62. 62.
    Grimm D, Kay MA, Kleinschmidt JA (2003) Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol Ther 7:839–850PubMedGoogle Scholar
  63. 63.
    Zolotukhin S, Byrne BJ, Mason E et al (1999) Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6:973–985PubMedGoogle Scholar
  64. 64.
    Summerford C, Samulski RJ (1998) Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438–1445PubMedCentralPubMedGoogle Scholar
  65. 65.
    Halbert CL, Allen JM, Miller AD (2001) Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol 75:6615–6624PubMedCentralPubMedGoogle Scholar
  66. 66.
    Tuszynski MH, Thal L, Pay M et al (2005) A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11:551–555PubMedGoogle Scholar
  67. 67.
    Mandel RJ (2010) CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer’s disease. Curr Opin Mol Ther 12:240–247PubMedGoogle Scholar
  68. 68.
    Wu K, Meyer EM, Bennett JA et al (2005) AAV2/5-mediated NGF gene delivery protects septal cholinergic neurons following axotomy. Brain Res 1061:107–113PubMedGoogle Scholar
  69. 69.
    Gene Therapy Clinical Trials Worldwide (2014), http://www.abedia.com/wiley/. John Wiley & Sons, Ltd
  70. 70.
    Bobo RH, Laske DW, Akbasak A et al (1994) Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076–2080PubMedCentralPubMedGoogle Scholar
  71. 71.
    Bankiewicz KS, Eberling JL, Kohutnicka M et al (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164:2–14PubMedGoogle Scholar
  72. 72.
    Krauze MT, Saito R, Noble C et al (2005) Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 103:923–929PubMedGoogle Scholar
  73. 73.
    Towne C, Schneider BL, Kieran D et al (2010) Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 17:141–146PubMedGoogle Scholar
  74. 74.
    Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177PubMedGoogle Scholar
  75. 75.
    Morgan D, Diamond DM, Gottschall PE et al (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408:982–985PubMedGoogle Scholar
  76. 76.
    Callaway E (2012) Alzheimer’s drugs take a new tack. Nature 489:13–14PubMedGoogle Scholar
  77. 77.
    Games D, Adams D, Alessandrini R et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523–527PubMedGoogle Scholar
  78. 78.
    Hsiao K, Chapman P, Nilsen S et al (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99–102PubMedGoogle Scholar
  79. 79.
    Yoshiyama Y, Higuchi M, Zhang B et al (2007) Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337–351PubMedGoogle Scholar
  80. 80.
    de Calignon A, Polydoro M, Suarez-Calvet M et al (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron 73:685–697PubMedCentralPubMedGoogle Scholar
  81. 81.
    Grueninger F, Bohrmann B, Czech C et al (2010) Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis 37:294–306PubMedGoogle Scholar
  82. 82.
    West MJ, Gundersen HJ (1990) Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296:1–22PubMedGoogle Scholar
  83. 83.
    Sze CI, Troncoso JC, Kawas C et al (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56:933–944PubMedGoogle Scholar
  84. 84.
    Arendash GW, King DL, Gordon MN et al (2001) Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891:42–53PubMedGoogle Scholar
  85. 85.
    Kiyota T, Yamamoto M, Schroder B et al (2009) AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther 17:803–809PubMedCentralPubMedGoogle Scholar
  86. 86.
    Kiyota T, Ingraham KL, Swan RJ et al (2012) AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP + PS1 mice. Gene Ther 19:724–733PubMedCentralPubMedGoogle Scholar
  87. 87.
    Hsia AY, Masliah E, McConlogue L et al (1999) Plaque-independent disruption of neural circuits in Alzheimer’s disease mouse models. Proc Natl Acad Sci U S A 96:3228–3233PubMedCentralPubMedGoogle Scholar
  88. 88.
    Chapman PF, White GL, Jones MW et al (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2:271–276PubMedGoogle Scholar
  89. 89.
    Selkoe DJ (2002) Alzheimer’s disease is a synaptic failure. Science 298:789–791PubMedGoogle Scholar
  90. 90.
    Terry RD, Masliah E, Salmon DP et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580PubMedGoogle Scholar
  91. 91.
    Galvan V, Bredesen DE (2007) Neurogenesis in the adult brain: implications for Alzheimer’s disease. CNS Neurol Disord Drug Targets 6:303–310PubMedGoogle Scholar
  92. 92.
    Abdipranoto A, Wu S, Stayte S et al (2008) The role of neurogenesis in neurodegenerative diseases and its implications for therapeutic development. CNS Neurol Disord Drug Targets 7:187–210PubMedGoogle Scholar
  93. 93.
    Biscaro B, Lindvall O, Hock C et al (2009) Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. J Neurosci 29:14108–14119PubMedGoogle Scholar
  94. 94.
    Kiyota T, Okuyama S, Swan RJ et al (2010) CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer’s disease-like pathogenesis in APP + PS1 bigenic mice. FASEB J 24:3093–3102PubMedCentralPubMedGoogle Scholar
  95. 95.
    Hefti F (1986) Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6:2155–2162PubMedGoogle Scholar
  96. 96.
    Bishop KM, Hofer EK, Mehta A et al (2008) Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol 211:574–584PubMedCentralPubMedGoogle Scholar
  97. 97.
    Arvanitakis ZPS, Bartus RT, Bennett D (2007) A phase I clinical trial of CERE-110 (AAV-NGF) gene delivery in Alzheimer's disease. American Academy of Neurology Annual Meeting, Boston, MAGoogle Scholar
  98. 98.
    Rafii MS, Baumann TL, Bakay RA et al (2014) A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimer’s Dement 10(5):571–581Google Scholar
  99. 99.
    Nagahara AH, Merrill DA, Coppola G et al (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat Med 15:331–337PubMedCentralPubMedGoogle Scholar
  100. 100.
    Mudo G, Bonomo A, Di Liberto V et al (2009) The FGF-2/FGFRs neurotrophic system promotes neurogenesis in the adult brain. J Neural Transm 116:995–1005PubMedGoogle Scholar
  101. 101.
    Kuhn HG, Winkler J, Kempermann G et al (1997) Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J Neurosci 17:5820–5829PubMedGoogle Scholar
  102. 102.
    Tao Y, Black IB, DiCicco-Bloom E (1997) In vivo neurogenesis is inhibited by neutralizing antibodies to basic fibroblast growth factor. J Neurobiol 33:289–296PubMedGoogle Scholar
  103. 103.
    Jin K, Sun Y, Xie L et al (2003) Neurogenesis and aging: FGF-2 and HB-EGF restore neurogenesis in hippocampus and subventricular zone of aged mice. Aging Cell 2:175–183PubMedGoogle Scholar
  104. 104.
    Baldauf K, Reymann KG (2005) Influence of EGF/bFGF treatment on proliferation, early neurogenesis and infarct volume after transient focal ischemia. Brain Res 1056:158–167PubMedGoogle Scholar
  105. 105.
    Kiyota T, Ingraham KL, Jacobsen MT et al (2011) FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer’s disease and has therapeutic implications for neurocognitive disorders. Proc Natl Acad Sci U S A 108:E1339–E1348PubMedCentralPubMedGoogle Scholar
  106. 106.
    Arendash GW, Gordon MN, Diamond DM et al (2001) Behavioral assessment of Alzheimer’s transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol 20:737–744PubMedGoogle Scholar
  107. 107.
    Westermark GT, Johnson KH, Westermark P (1999) Staining methods for identification of amyloid in tissue. Methods Enzymol 309:3–25PubMedGoogle Scholar
  108. 108.
    Selkoe DJ (2009) Thioflavin-S staining protocol. http://www.alzforum.org/sites/default/files/protocol_Thioflavin_S_staining_of_brain_tissue.pdf. Accessed 16 Nov 2014
  109. 109.
    Guo P, El-Gohary Y, Prasadan K et al (2012) Rapid and simplified purification of recombinant adeno-associated virus. J Virol Methods 183:139–146PubMedCentralPubMedGoogle Scholar
  110. 110.
    Miyake K, Miyake N, Yamazaki Y et al (2012) Serotype-independent method of recombinant adeno-associated virus (AAV) vector production and purification. J Nippon Med Sch 79:394–402PubMedGoogle Scholar
  111. 111.
    Wu Z, Miller E, Agbandje-McKenna M et al (2006) Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80:9093–9103PubMedCentralPubMedGoogle Scholar
  112. 112.
    Stroes ES, Nierman MC, Meulenberg JJ et al (2008) Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol 28:2303–2304PubMedGoogle Scholar
  113. 113.
    Takeda S, Takahashi M, Mizukami H et al (2004) Successful gene transfer using adeno-associated virus vectors into the kidney: comparison among adeno-associated virus serotype 1-5 vectors in vitro and in vivo. Nephron Exp Nephrol 96:e119–e126PubMedGoogle Scholar
  114. 114.
    Maguire AM, High KA, Auricchio A et al (2009) Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374:1597–1605PubMedGoogle Scholar
  115. 115.
    Davidson BL, Stein CS, Heth JA et al (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 97:3428–3432PubMedCentralPubMedGoogle Scholar
  116. 116.
    Akache B, Grimm D, Pandey K et al (2006) The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80:9831–9836PubMedCentralPubMedGoogle Scholar
  117. 117.
    Qing K, Mah C, Hansen J et al (1999) Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5:71–77PubMedGoogle Scholar
  118. 118.
    Summerford C, Bartlett JS, Samulski RJ (1999) AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5:78–82PubMedGoogle Scholar
  119. 119.
    Asokan A, Hamra JB, Govindasamy L et al (2006) Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol 80:8961–8969PubMedCentralPubMedGoogle Scholar
  120. 120.
    Kashiwakura Y, Tamayose K, Iwabuchi K et al (2005) Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 79:609–614PubMedCentralPubMedGoogle Scholar
  121. 121.
    Glushakova LG, Lisankie MJ, Eruslanov EB et al (2009) AAV3-mediated transfer and expression of the pyruvate dehydrogenase E1 alpha subunit gene causes metabolic remodeling and apoptosis of human liver cancer cells. Mol Genet Metab 98:289–299PubMedCentralPubMedGoogle Scholar
  122. 122.
    Hadaczek P, Eberling JL, Pivirotto P et al (2010) Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 18:1458–1461PubMedCentralPubMedGoogle Scholar
  123. 123.
    Mease PJ, Hobbs K, Chalmers A et al (2009) Local delivery of a recombinant adeno-associated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study. Ann Rheum Dis 68:1247–1254PubMedGoogle Scholar
  124. 124.
    Rabinowitz JE, Rolling F, Li C et al (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76:791–801PubMedCentralPubMedGoogle Scholar
  125. 125.
    Ling C, Lu Y, Kalsi JK et al (2010) Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther 21:1741–1747PubMedCentralPubMedGoogle Scholar
  126. 126.
    Weber M, Rabinowitz J, Provost N et al (2003) Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther 7:774–781PubMedGoogle Scholar
  127. 127.
    Kaludov N, Brown KE, Walters RW et al (2001) Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 75:6884–6893PubMedCentralPubMedGoogle Scholar
  128. 128.
    Walters RW, Yi SM, Keshavjee S et al (2001) Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 276:20610–20616PubMedGoogle Scholar
  129. 129.
    Di Pasquale G, Davidson BL, Stein CS et al (2003) Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9:1306–1312PubMedGoogle Scholar
  130. 130.
    Adriaansen J, Khoury M, de Cortie CJ et al (2007) Reduction of arthritis following intra-articular administration of an adeno-associated virus serotype 5 expressing a disease-inducible TNF-blocking agent. Ann Rheum Dis 66:1143–1150PubMedCentralPubMedGoogle Scholar
  131. 131.
    Weller ML, Amornphimoltham P, Schmidt M et al (2010) Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med 16:662–664PubMedCentralPubMedGoogle Scholar
  132. 132.
    Gao GP, Alvira MR, Wang L et al (2002) Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 99:11854–11859PubMedCentralPubMedGoogle Scholar
  133. 133.
    Fang H, Lai NC, Gao MH et al (2012) Comparison of Adeno-Associated Virus Serotypes and Delivery Methods for Cardiac Gene Transfer. Hum Gene Ther Methods 23(4):234–241PubMedCentralPubMedGoogle Scholar
  134. 134.
    Blankinship MJ, Gregorevic P, Allen JM et al (2004) Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther 10:671–678PubMedGoogle Scholar
  135. 135.
    Shen S, Bryant KD, Brown SM et al (2011) Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286:13532–13540PubMedCentralPubMedGoogle Scholar
  136. 136.
    Mori S, Takeuchi T, Enomoto Y et al (2008) Tissue distribution of cynomolgus adeno-associated viruses AAV10, AAV11, and AAVcy.7 in naturally infected monkeys. Arch Virol 153:375–380PubMedGoogle Scholar
  137. 137.
    Anderson SM, Famous KR, Sadri-Vakili G et al (2008) CaMKII: a biochemical bridge linking accumbens dopamine and glutamate systems in cocaine seeking. Nat Neurosci 11:344–353PubMedGoogle Scholar
  138. 138.
    Quinn K, Quirion MR, Lo CY et al (2011) Intranasal administration of adeno-associated virus type 12 (AAV12) leads to transduction of the nasal epithelia and can initiate transgene-specific immune response. Mol Ther 19:1990–1998PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of Pharmacology and Experimental Therapeutics and Graduate Program in NeuroscienceBoston University School of MedicineBostonUSA
  2. 2.Department of Pharmacology and Experimental NeuroscienceUniversity of Nebraska Medical CenterOmahaUSA
  3. 3.Department of NeurologyBoston University School of MedicineBostonUSA
  4. 4.Laboratory of Molecular NeuroTherapeutics, Department of Pharmacology and Experimental Therapeutics and NeurologyBoston University School of MedicineBostonUSA

Personalised recommendations